Complication Rates in Patients With Negative Axillary Nodes 10 Years After Local Breast Radiotherapy After Either Sentinel Lymph Node Dissection or Axillary Clearance

被引:52
|
作者
Wernicke, A. Gabriella [1 ]
Shamis, Michael [4 ]
Sidhu, Kulbir K. [5 ]
Turner, Bruce C. [5 ]
Goltser, Yevgenyia [7 ]
Khan, Imraan [3 ]
Christos, Paul J. [2 ]
Komarnicky-Kocher, Lydia T. [6 ]
机构
[1] Cornell Univ, Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY 10065 USA
[2] Cornell Univ, Weill Cornell Med Coll, Dept Publ Hlth, Div Biostat & Epidemiol, New York, NY 10065 USA
[3] SUNY Stony Brook, Dept Biol Sci, Stony Brook, NY 11794 USA
[4] St George Univ, Dept Med Sci, Grenada, WI USA
[5] Thomas Jefferson Univ Hosp, Dept Radiat Oncol, Philadelphia, PA 19107 USA
[6] Drexel Univ Hosp, Dept Radiat Oncol, Philadelphia, PA USA
[7] Brandeis Univ, Dept Biol Sci, Waltham, MA USA
关键词
sentinel lymph node; axillary lymph node dissection; breast cancer; radiotherapy; complication rates; lymphedema; paresthesia; decreased range of motion; seroma; axillary web syndrome; TANGENTIAL IRRADIATION TECHNIQUE; WEB SYNDROME; RADIATION-THERAPY; TOTAL MASTECTOMY; FOLLOW-UP; LEVEL-I; CANCER; BIOPSY; TRIAL; FIELDS;
D O I
10.1097/COC.0b013e3182354bda
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We assess complication rates in node negative breast cancer patients treated with breast radiotherapy (RT) only after sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND). Materials and Methods: Between 1995 and 2001, 226 women with AJCC stage I-II breast cancer were treated with lumpectomy, either SLND or SLND+ALND, and had available toxicities in follow-up: 111/136 (82%) and 115/129 (89%) in SLND and ALND groups, respectively. RT targeted the breast to median dose of 48.2 Gy (range, 46.0 to 50.4 Gy) without axillary RT. Chi-square tests compared complication rates of 2 groups for axillary web syndrome (AWS), seroma, wound infection, decreased range of motion of the ipsilateral shoulder, paresthesia, and lymphedema. Results: Median follow-up was 9.9 years (range, 8.3-15.3 y). Median number of nodes assessed was 2 (range, 1-5) in SLND and 18 (range, 7-36) in ALND (P < 0.0001). Acute complications occurred during the first 2 years and were AWS, seroma, and wound infection. Incidences of seroma 5/111 (4.5%) in SLND and 16/115 (13.9%) in ALND (P < 0.02, respectively) and wound infection 3/111 (2.7%) in SLND and 10/115 (8.7%) in ALND (P < 0.05, respectively) differed significantly. AWS was not statistically different between the groups. At 10 years, the only chronic complications decreased were range of motion of the shoulder 46/111 (41.4%) in SLND and 92/115 (80.0%) in ALND (P < 0.0001), paresthesia 12/111 (10.8%) in SLND and 39/115 (33.9%) in ALND (P < 0.0001), and lymphedema assessed by patients 10/111 (10.0%) in SLND and 39/115 (33.9%) in ALND (P < 0.0001). Chronic lymphedema, assessed by clinicians, occurred in 6/111 (5.4%) in SLND and 21/115 (18.3%) in ALND cohorts, respectively (P < 0.0001). Conclusions: Our mature findings support that in patients with negative axillary nodal status SLND and breast RT provide excellent long-term cure rates while avoiding morbidities associated with ALND or addition of axillary RT field.
引用
收藏
页码:12 / 19
页数:8
相关论文
共 50 条
  • [1] Axillary lymphocele after axillary dissection or sampling of sentinel lymph node in breast cancer
    Bijek, JH
    Aucouturier, JS
    Doridot, V
    Ghemari, T
    Nos, C
    [J]. BULLETIN DU CANCER, 2005, 92 (02) : 179 - 183
  • [2] Axillary lymph node dissection in breast cancer patients after sentinel node biopsy
    Jessing, Christina
    Langhans, Linnea
    Jensen, Maj-Britt
    Talman, Maj-Lis
    Tvedskov, Tove Filtenborg
    Kroman, Niels
    [J]. ACTA ONCOLOGICA, 2018, 57 (01) : 166 - 169
  • [3] Axillary recurrence after negative sentinel lymph node biopsy without axillary dissection: a study on 479 breast cancer patients
    Zavagno, G
    Carcoforo, P
    Franchini, Z
    Renier, M
    Barutta, L
    De Salvo, GL
    Maravegias, K
    Capitanio, G
    Nitti, D
    Lise, M
    [J]. EJSO, 2005, 31 (07): : 715 - 720
  • [4] Patients with breast cancer and positive sentinel nodes: Axillary dissection or axillary radiotherapy?
    Zippel, D
    Papa, M
    [J]. ARCHIVES OF SURGERY, 2003, 138 (10) : 1159 - 1159
  • [5] Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer
    Palesty, JA
    Foster, JM
    Hurd, TC
    Watroba, N
    Rezaishiraz, H
    Edge, SB
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2006, 93 (02) : 129 - 132
  • [6] Morbidity after regional nodes radiotherapy in early breast cancer patients having axillary lymph node dissection
    Nielsen, H.
    Friis, R.
    Linnet, S.
    Offersen, B.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S335 - S335
  • [7] Axillary Recurrence after Negative Sentinel Lymph Node Dissection in Three Elderly Triple Negative Breast Cancer Patients
    Sharma, M.
    Skinner, K. A.
    Hicks, D. G.
    Tang, P.
    [J]. MODERN PATHOLOGY, 2012, 25 : 66A - 66A
  • [8] Axillary Recurrence after Negative Sentinel Lymph Node Dissection in Three Elderly Triple Negative Breast Cancer Patients
    Sharma, M.
    Skinner, K. A.
    Hicks, D. G.
    Tang, P.
    [J]. LABORATORY INVESTIGATION, 2012, 92 : 66A - 66A
  • [9] Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial)
    Garcia-Tejedor, Amparo
    Ortega-Exposito, Carlos
    Salinas, Sira
    Luzardo-Gonzalez, Ana
    Falo, Catalina
    Martinez-Perez, Evelyn
    Perez-Montero, Hector
    Soler-Monso, M. Teresa
    Bajen, Maria-Teresa
    Benitez, Ana
    Ortega, Raul
    Petit, Anna
    Guma, Anna
    Campos, Miriam
    Pla, Maria J.
    Pernas, Sonia
    Penafiel, Judith
    Yeste, Carlos
    Gil-Gil, Miguel
    Guedea, Ferran
    Ponce, Jordi
    Laplana, Maria
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [10] The Effect of Radiotherapy On Axillary Recurrence After Negative Sentinel Lymph Node Biopsy
    Stafyla, V.
    Vanderstrappen, K.
    Rotmensz, N.
    Santilo, B.
    Veronesi, P.
    Gentilini, O. D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S218 - S218